Currently, there is no known medical treatment that hastens the repair of damaged nerve and muscle. Using IGF-1 transgenic mice that specifically express human recombinant IGF-1 in skeletal muscle, we test the hypotheses that targeted gene expression of IGF-1 in skeletal muscle enhances motor nerve regeneration after a nerve crush injury. The IGF-1 transgene affects the initiation of the muscle repair process after nerve injury as shown by increased activation of SCA-1positive myogenic stem cells. Increased satellite cell differentiation and proliferation are observed in IGF-1 transgenic mice, shown by increased expression of Cyclin D1, MyoD, and myogenin. Expression of myogenin and nicotinic acetylcholine receptor subunits, initially increased in both wild-type and IGF-1 transgenic mice, are restored to normal levels at a faster rate in IGF-1 transgenic mice, which indicates a rescue of nerve-evoked muscle activity. Expression of the IGF-1 transgene in skeletal muscle results in accelerated recovery of saltatory nerve conduction, increased innervation as detected by neurofilament expression, and faster recovery of muscle mass. These studies demonstrate that local expression of IGF-1 augments the repair of injured nerve and muscle.
T he repair of peripheral nerves damaged by injury or disease is often incomplete despite vast improvements in microsurgical techniques. There still exists an urgent need to develop new medical treatments that hastens the repair of damaged nerve and muscle. Neurotrophic factors that play a critical role in the development and regeneration of muscle and nerve have the potential for being used as gene therapies to enhance the repair of injured and diseased nerves and muscle. One candidate factor exerting both myogenic and neurotrophic factor activities is insulin-like growth factor-1 (IGF-1).
IGF-1 is a potent neurotrophic factor for motor neurons. It is a survival factor for cultured spinal cord motoneurons and helps to maintain high levels of choline acetyltransferase activity (1, 2) . Neurite outgrowth is induced in cultured spinal cord motor neurons both in the presence and absence of non-neuronal cells (3, 4) . In vivo studies show that IGF-1 can rescue motoneurons from axotomyinduced death or programmed cell death (2, 5) . Local infusion of IGF-1 stimulates nerve regeneration in crushed (6, 7) or freeze-injured sciatic nerve (8) . Sensory regeneration in sciatic nerve is enhanced in diabetic rats by exogenous application of IGF-1 near the nerve injury (9) . Conversely, local infusion of IGF antiserum significantly inhibits spontaneous regeneration of motor and sensory nerves (10, 11) .
Nerve sprouting within skeletal muscles is an essential restorative process in response to an injury or a pathological condition. IGF-1 increases intramuscular nerve sprouting 10-fold when administered subcutaneously to normal adult rats (3) . Injection of IGF binding protein 4, an inhibitor of IGF-1 activity, completely blocks the neurite promoting activity of muscle extract (12) , further implicating IGF-1 as a neurite sprouting factor. These studies are supported by experiments showing that subcutaneously injected IGF-1 accumulates at the neuromuscular junction and in neuromuscular nerves and induces the expression of the nerve growth associated protein GAP-43 in the motor neuron perikarya (13, 14) .
IGF-1 is also a potent myogenic factor, promoting myoblast proliferation, myogenic differentiation, and myotube hypertrophy (15) . Evidence of the myogenic effects of IGF-1 are demonstrated by studies showing increased muscle myofiber hypertrophy in transgenic mice overexpressing IGF-1 in skeletal muscle (16) . In regenerating muscle IGF-1 expression is increased early in muscle satellite cells and continues to increase through the formation of myofibers (17, 18) . These studies suggest that the potential of IGF-1 for inducing muscle repair may be in its ability to function as both a myogenic factor as well as a neurotrophic factor.
Given the effects of IGF-1 in the regeneration of nerve and muscle, we reasoned that localized secretion of IGF-1 in regenerating muscle cells should facilitate motor nerve and muscle repair after nerve injury. This hypothesis was tested in an IGF-1 transgenic line that specifically expresses human IGF-1 in skeletal muscle, via the skeletal α-actin promoter (16) . Our studies show that when the sciatic nerve is injured, increased local expression of IGF-1 in muscle hastens motor nerve and muscle repair.
MATERIALS AND METHODS

IGF-1 Transgenic Animals
IGF-1 transgenic mice expressing the human IGF-1 transgene in skeletal muscle were produced from a vector containing 411 nucleotides of the skeletal α actin promoter/enhancer (16) . IGF-1 transgenic homozygous females (+/+) and non-transgenic wild-type female littermates (-\-) (28-32 g) were used in this study. Transgene copy number was determined by comparing the hybridization signal from 10 µg of mouse genomic DNA in a Southern blot, quantitated by using a Betascope model 603 analyzer (Betagen, Waltham, MA). Homozygous mice were also identified by backcrossing IGF-1-positive mice to wild-type ICR mice.
Nerve Injury Paradigm
Mice were anesthetized with Avertin (0.2 ml/10 g body weight, injected IP in a 1.25% solution). To induce nerve crush injury, sciatic nerve exposed mid-thigh was crushed 2 mm distal to the sciatic notch with Dumonts #5 forceps for 30 s. The wound was closed with sterile clips, and the mice were placed on a warming pad for 1 h or until the animals awoke. The contralateral side left intact was used as a control.
Chemiluminescence Enzyme-linked Immunosorbant Assay (CELISA)
Muscle was homogenized in RIPA buffer [1× phosphate buffered saline (PBS), 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS)] with a complete protease inhibitor cocktail (Roche, Indianapolis, IN), and protein was assayed by using BCA reagent (Pierce, Rockford, IL). To prepare 96-well ELISA plates (Nunc Maxicoat, Nalge Nunc International, Rochester, NY), wells were coated with 50 µl of nitrocellulose (HAFT Membranes, Millipore, Bedford MA), which was solubilized for 30 min in methanol and centrifuged at 5000 x g. Wells were treated for 15 min at rt, the solution was removed, and the wells were allowed to dry. The wells were coated with 50 µl of protein samples, diluted to 0.1 mg/ml in dH 2 O, and were allowed to dry overnight in a laminar flow hood, then washed twice in PBS. Anti-mouse monoclonal antibodies myogenin, MyoD F5D, (DAKO Corp., Carpinteria, CA), cyclin-D1 (Santa Cruz Biotech, Santa Cruz, CA), SCA-1 D7 (PharMingen, San Diego, CA), anti human IGF-1 (human and mouse specific; DSL, Webster, TX) and anti neurofilament M (mouse specific; Chemicon, Temecula, CA) were biotinylated by using a DAKO ARK kit according to the manufacturer's instructions. Incubations were performed overnight at 4°C at antibody concentrations of 1.25-5.00 µg/ml in 50 µl volumes. Plates were washed 3×, 15 min each, in PBS/Tween (0.05%) and were incubated with 2 µg/ml streptavidin-peroxidase (Jackson ImmunoResearch) for 1 h at rt. After washing, ECL chemiluminescence reagent (Amersham) was diluted 1:2 in PBS and 50 µl was added to the wells and luminescence was quantified on a Perkin Elmer HTS 7000 Plus Bioassay reader with HT 2.0 software by using an integration time of 500 msec and a gain of 100).
Immunohistochemistry
For anti-MyoD and myogenin immunohistochemistry, gastrocnemius muscle was fixed in formalin, embedded in paraffin, cut to 10 µm, and then deparaffinized by using standard Xylene and ethanol treatments. For anti-Sca-1, -cyclinD1, and -neurofilament M, gastrocnemius muscle was fixed in 4% paraformaldehyde and embedded in O.C.T. compound (Tissue-Tek), and tissues were cut to 7-10 µm. For both fixations, endogenous peroxidase was quenched by a 10-min incubation with 3% peroxide in PBS, pH 7.4. After 3 washes, sections were incubated overnight at 4°C with 2.5 ug/ml of biotinylated monoclonal antibodies MyoD, Myogenin, Sca-1, cyclinD1, and neurofilament M, diluted in PBS. After washing, sections were reacted with 2 µg/ml streptavidin-HRP for 1 h at rt. After being washed 3× in PBS, sections were reacted with diaminobenzidine chromogen/H 2 O 2 for 5-30 min and then washed in distilled H 2 O. Mounting media (Shandon Immu-Mount; Shandon, Pittsburgh, PA) was applied and the sections were coverslipped.
Northern Blot Analysis
Northern blots were prepared by size fractionation of total RNA samples, run on 1% agarose, 2.2 M formaldehyde gels and capillary transfer to GeneScreen nylon membranes (Dupont NEN), then cross-linked to the membranes (Stratagene UV linker). All pre-hybridizations and hybridizations were performed in 50% (v/v) formamide, 5× SSPE, 5× Denhardt's, 0.1% (w/v) bovine serum albumin, 0.1% (w/v) polyvinylpyrrolidone, 0.1% (w/v) ficol, 1% (w/v) SDS, 10% (w/v) dextran sulfate, and 200 µg/ml sheared salmon sperm DNA. Northern blots were hybridized with 32 P-labeled DNA for 16 h at 45°C with 10 6 cpm/ml probe. Membranes were washed 2 × 30 min in 2× SSPE, 1% SDS at 68°C, and then 1× 30 min in 0.5 SSPE, 0.1% SDS at 55°C. DNA probes were labeled with 32 P by using Pharmacia DNA labeling kit. Blots were exposed to X-ray film (Kodak X-Omat AR) at -70°C with intensifying screens. Probes used in this study were myogenin (1.6 Kb), and 18S (316 bp). Acetlycholine receptor-gamma probe (500 bp) was a gift from J. Patrick (Division of Neuroscience, Baylor College of Medicine).
Nerve Conduction Velocity (NCV)
NCV was measured with a Dantec Neuromatic 2000 EMG/EP system. Nerves were bathed in mineral oil to maintain temperature and to keep the nerve moist. The animals were kept on a warming pad throughout the procedure. The sciatic nerve was completely elevated from the surrounding muscle without stretching the nerve. The sciatic nerve was stimulated 2 mm distal to the crush site with 0.2 millisecond square pulses over a 30 s time frame. The pulses were delivered through dipolar electrodes held under the nerve (distal to crush site), and potentials were recorded from the gastrocnemius by using a concentric electrode. After the first recordings, the dipolar electrode was repositioned 0.6 cm distally and recordings were repeated. The latencies were measured from photographs of the oscilloscope recordings. The conduction velocity was calculated by using the following formula: CV = D/L where D = distance between recordings; L = action latency in milliseconds and CV= conduction velocity in m/sec. Three repetitions of nerve conduction pulses were made for each animal.
Statistical Analysis
For CELISA analysis, the numbers of replicate samples for each group were done in quadruplicate. The values are expressed as percentage of control of wild-type non-injured muscle (defined as 100%). The percent values were averaged, and the data were presented as the mean +/− SEM (n=4). For nerve conduction experiments, six animals per group (n=6) were tested, and the values were averaged +/− SEM. Comparisons between experimental groups were analyzed by non-paired, onetailed students t-test. P values < 0.05 were defined as statistically significant. In all studies, three separate experiments were performed.
RESULTS
IGF-1 transgene is specifically expressed in skeletal muscle
The avian skeletal α-actin gene was used as a template to construct a myogenic vector to direct expression of a human IGF-I cDNA in striated muscle of transgenic mice (Fig. 1A) . With this system, expression of human IGF-I in skeletal muscle is elevated almost 50-fold. Human IGF-I levels in serum are not increased by transgene expression, which suggests that the effects of transgene expression are localized to skeletal muscle (16) . In the present study, we further examined the expression of the IGF-1 transgene in muscle and neural tissues. The RNA gel blot shown in Figure 1B indicates that the IGF-1 transgene is highly expressed in extensor digitorum longus and gastrocnemius muscles. Human IGF-I transcripts are totally absent in sciatic nerve, spinal cord, and brain tissues. Thus, muscle serves as the sole source of exogenous IGF-I.
We have analyzed expression of IGF-1 in wild-type and IGF-1 transgenic muscle following sciatic nerve crush injury through the course of initial muscle repair and neuromuscular innervation. Studies show that IGF-1 plays a role in the regeneration process (Fig. 2) . In wild-type mice, a small but significant rise in IGF-1 is detected at three days post-injury compared with sham-operated muscle and increases nearly threefold after 2 weeks. In contrast, the levels of IGF-1 protein in transgenic mice are fivefold higher, reflecting the expression of the human IGF-1 transgene. IGF-1 levels remained at these elevated levels in transgenic muscle until 5 days post-injury, at which time IGF-1 levels rise an additional 2.5-fold before gradually declining. The additional elevation of IGF-1 after 5 days in transgenic mice could be due to the contribution of murine IGF-1 expressed in response to injury. These results show that IGF-1 expression is normally increased in injured muscle as part of the regeneration process. IGF-1 transgenic muscle also undergo a rise in endogenous IGF-1 in spite of the dramatically elevated resting levels.
Local IGF-1 overexpression in skeletal muscle initiates muscle proliferation differentiation pathways after nerve injury
Proliferation of quiescent satellite cells is an initial step in the progression toward differentiated muscle. The proliferation potential of muscle satellite cells after nerve injury is detected with anticyclin D1 and quantitated by CELISA. Before nerve injury, cyclin D1 is not detectable in either IGF-1 transgenic or wild-type muscle (Fig. 3A) . Expression of cyclin D1 in IGF-1 transgenic muscle peaks 1 day after injury, increasing fourfold then declining 3 and 5 days post-injury. In contrast, cyclin D1 expression in wild-type muscle is not detected until day 3, increasing 0.5-fold before declining to basal levels at day 5 post-injury. Immunohistochemical analysis shows cyclin D1 positive cells to be primarily satellite cells. We do not observe Schwann cell proliferation at these time points, although it is still possible that some Schwann cell proliferation may be occurring. As shown in Figure 3B , IGF-1 muscle has significantly more proliferating satellite cells than does wildtype muscle after a nerve injury. Therefore, IGF-1 transgene expression induces satellite cell proliferation earlier and to a greater extent than in wild-type muscle, after nerve injury.
Stem cell antigen (Sca-1)-positive cells in mouse skeletal muscle represent a population of multipotent stem cells derived from bone marrow hemopoietic stem cells (19) (20) (21) . In intact animals, Sca-1-positive cells are elevated nearly 50% in IGF-1 transgenic muscle compared with wild-type, indicating that the satellite cell pool is increased by the IGF-1 transgene during normal development (Fig. 4A) . At day 1 post-injury, Sca-1 expression peaks to a level sevenfold higher in IGF-1 transgenic muscle and then begins to decline after day 3. In wild-type muscle, increases of Sca-1 are not detected until day 3, increasing twofold, then declining to near basal levels at day 5. At day 3, IGF-1 transgenic muscle has levels 2.5-fold higher than wild types at the same time point. Immunohistochemical analysis reveals that SCA-1 is expressed in satellite cells, residing between the sarcolemma and the basal lamina of the muscle fibers. As shown in Figure 4B , non-injured muscle contains Sca-1 positive satellite cells. In contrast, higher basal immunoreactivity is shown in non-injured IGF-1 transgenic muscle. At 3 days post-injury, wild-type muscle are beginning to exhibit increased Sca-1 immunoreactivity in satellite cells, but IGF-1 transgenic muscle still has significantly higher Sca-1 immunoreactivity at this time point. The time course of Sca-1 and CyclinD1 expression is identical in nerve injured IGF-1 transgenic mice (Figs. 3 and 4) , suggesting that increased Sca-1 expression by IGF-1 reflects the proliferation of SCA-1-positive satellite cells.
MyoD and myogenin are muscle regulatory factors that have a central role in the activation and differentiation of muscle satellite cells (22) . MyoD functions in determining the myogenic fate of satellite cells, whereas myogenin appears to function in activation terminal muscle cell differentiation (23, 24) . As shown in Figure 5A , there are significantly more basal amounts of MyoD in non-injured IGF-1 transgenic muscle, showing a constant but low level of myogenesis occurring in IGF-1 transgenic muscle. One day after injury, IGF-1 transgenic muscle exhibits a sevenfold increase in MyoD expression from its basal levels before gradually declining. In contrast, MyoD is not detectable in non-injured wild-type mice. Wild-type mice first exhibit detectable MyoD expression 3 days post-injury, but the expression always remains significantly lower than that of IGF-1 transgenic muscle. As shown in Figure 5B , MyoD immunoreactivity is localized to satellite cells in IGF-1 non-injured muscle and intensity of immunoreactivity is significantly increased at 1 day post-injury. In contrast, MyoD-positive cells are not detected in non-injured wild-type muscle and is only scarcely detectable 1 day post-injury.
Similar to MyoD expression, a low level of myogenin is also expressed in non-injured IGF-1 transgenic muscle (Fig. 6A) but not in intact wild-type mice. After 1 day post-injury, IGF-1 transgenic muscle exhibits a 4.7-fold increase in myogenin expression, then gradually declines. In contrast, wild-type mice do not exhibit detectable myogenin expression until day 5 post-injury, but the expression remains significantly below that of IGF-1 muscle. As shown in Figure 6B , myogenin immunoreactivity is localized in satellite cells of non-injured IGF-1 muscle. Immunoreactivity increases dramatically at 1 day post-injury, whereas myogenin is not yet detected in non-injured wild-type muscle. Given that increased satellite cell proliferation is evident in IGF-1 transgenic muscle, the increased intensity of myogenin and Myo-positive cells is due, in part, to increased satellite cell density. Thus, these results show that IGF-1 intensifies muscle regeneration after nerve injury by accelerating the myogenic differentiation pathway.
Local IGF-1 overexpression in skeletal muscle enhances peripheral nerve regeneration after nerve injury Neurofilaments are a major cytoskeleton protein of axons. Using neurofilament 150 kD expression as a marker for muscle innervation, we analyzed the effects of locally expressed IGF-1 on axon growth after nerve injury, by CELISA and immunohistochemistry. As shown in Figure 7A , neurofilament expression is increased approximately twofold in IGF-1 transgenic muscle at 2 weeks post-injury, compared with injured wild-type muscle, and remains elevated through 8 weeks of recovery. Immunohistochemical analysis shows increased innervation into muscle of IGF-1 transgenic mice after 3 weeks post-injury compared with injured wild-type mice (Fig. 7B) . These results show that the IGF-1 transgene accelerates re-innervation of muscle after a nerve injury.
In adults, muscle differentiation factors and nicotinic acetlycholine receptor subunits are upregulated by chemical or mechanical denervation of muscle, but return to baseline levels upon functional innervation or after electrical stimulation (25) (26) (27) . As a measure of reinnervation of skeletal muscle, we evaluate the temporal expression of myogenin and γ AchR subunit mRNA in IGF-1 transgenic and wild-type mice after a sciatic nerve crush injury (Fig. 8) . Two weeks after injury, myogenin and γ AchR mRNA transcripts are still present in both IGF-1 transgenic mice (lane 4) and wild type controls (lane 2), compared with intact mice (lanes 1 and 3) . Within 3 weeks post injury, myogenin and γ AchR mRNA levels return to uninjured levels in muscles of IGF-1 transgenic mice (lane 8). In contrast, myogenin and γ AchR mRNA expression remains elevated in muscle from nerve injured wild types (lane 6). The hastened restoration of myogenin and γ AchR mRNA to control levels strongly suggested that muscles of IGF-1 transgenic mice are reinnervated more rapidly after injury.
Saltatory nerve conduction can only occur in myelinated, intact, nerve muscle synapses. Therefore, it is an excellent marker for functional recovery of movement (Fig. 9) . Nerve conduction velocity (NCV) is not evident 2 weeks after injury in both IGF-1 transgenic and wild type mice, indicating that functional nerve-muscle synapses are not yet reestablished. In IGF-1 transgenic mice, NCV is first detectable 3 weeks after injury, but is still undetectable in wild type mice. After 4 weeks, IGF-1 transgenic mice have recovered 70% of normal NCV whereas injured wild type nerve have recovered only 34% of NCV. By eight weeks, nerve injured IGF-1 transgenic and wild type controls recover 76% and 55%, respectively, of their function. These results show that the IGF-1 transgene enhanced both the rate and degree of functional nerve recovery in the muscle after nerve injury.
The return of gastrocnemius muscle mass after nerve injury was assessed in IGF-1 transgenic mice and wild type controls. Muscle mass is typically decreased after a nerve injury and then increases in parallel with reinnervation of the muscle. As shown in Fig. 10 , muscle mass in wild type mice declines to 50% of normal weight after 2 weeks post injury. In contrast, muscle mass in IGF-1 transgenic mice decline to only 75% of normal weight. After 8 weeks of recovery, IGF-1 transgenic mice regained 96% of normal weight, whereas wild type mice regained only 83%. These results show that the IGF-1 transgene reduces the degree of atrophy and hastens recovery of normal muscle mass after nerve injury.
DISCUSSION
In our studies, we show that IGF-1 has a role in inducing the initial phases of muscle differentiation in response to a peripheral nerve injury by elevating satellite cell proliferation. Satellite cells are normally quiescent but, when activated, re-enter the cell cycle in response to stress induced by weight-bearing exercise or trauma (28, 29, 30) . We show that satellite cells of nerve injured wild type muscle undergo proliferation as shown by increased cyclin D1-postiive cells, with peak activity at day 3 post injury. In contrast, the IGF-1 transgene causes robust satellite cell proliferation after just 1 day post injury. This indicates that IGF-1 has a major role in initiating satellite cells proliferation in response to a nerve injury, and that overexpression of IGF-1 results in a hastened proliferation response.
There is a concomitant increase in SCA-1 -positive satellite cells which parallels the expression of cyclin D1. The SCA-1 marker belongs to the Ly-6 gene family, and is a marker of hematopoietic stem cells (20) . SCA-1 has been shown to be present on a population of multipotent stem cells in a murine skeletal muscle (19, 21) . In non-injured muscle, both wild type and IGF-1 SCA-1-positive cells populate the muscle and are dormant (in G0 phase), given that no cyclin D1 expression is detected. With injury, the elevated levels of SCA-1 and cyclin D1 positive cells in IGF-1 transgenic muscle show that IGF-1 induces the expansion of the satellite stem cell compartment. Multiple rounds of proliferation are characteristic of myogenic precursor cells that eventually fuse to existing or new fibers (28) . Thus, our results show that the IGF-1 transgene induces and accelerates muscle repair by augmenting the proliferation phase of satellite cell differentiation.
Studies in wild type mice show a temporal progression of MyoD and myogenin in response to a peripheral nerve injury. Before nerve injury, quiescent satellite cells do not express MyoD or myogenin, which is in agreement with studies in cultured muscle cells (31, 32, 33) . Following nerve crush injury in wild type mice, MyoD expression peaks at 3 days post injury, in parallel with cyclin D expression. The parallel increase of MyoD and cyclin D1 after nerve injury is consistent with in vitro studies showing that Myo D is expressed in proliferating satellite cells (32) . MyoD's differentiating function is known to remain inactive due to the growth promoting activity of cyclin D1, but becomes active in satellite cells when growth promoting signals decline (32, 33, 34, 35) . Following MyoD expression we show myogenin expressed later (5 days post injury) in the myogenic pathway, which is consistent with its role in terminal differentiation (32, 35) .
In contrast, IGF-1 induces a rapid induction of the myogenic program. Without injury, a low but significant expression of both MyoD and myogenin suggests the IGF-1 transgene creates a resting set of satellite cells already committed to the myogenic lineage. After nerve injury, the IGF-1 transgene induces a more dramatic increase in MyoD and myogenin compared with wild type muscle, which is consistent with IGF-1's role in inducing myogenic factors in vitro and in vivo (16, 36,37,38.) . The rise of these factors in IGF-1 transgenic muscle is rapid and simultaneous, occurring only 1 day post injury. Combined with the parallel increase in cyclin D1-positive satellite cells, these results suggests that IGF-1 acts simultaneously to induce activation of proliferation and differentiation. It is therefore probable that distinct subpopulations of precursor cells are either committed satellite cells ready for immediate differentiation or precursor stem cells destined for proliferation (28) . The increase in the Sca-1 cell population in injured muscle may represent the early stem cells undergoing proliferation before entering the differentiation pathway. The satellite cell populations expressing MyoD and myogenin in the non-injured IGF-1 mouse may represent a committed precursor whose expression is strongly increased 1 day after injury. Therefore, IGF-1 acts early in the regeneration process by activating both committed and uncommitted satellite cells to enter the differentiation program.
The rapid induction of proliferation and differentiation in IGF-1 transgenic mice confirms that IGF-1 acts early to induce muscle regeneration after injury. However, other factors may be also working in concert with IGF-1 to initiate the myogenic program. For example, hepatocyte growth factor (HGF) is a mitogen and chemotactic factor that may be involved in early activation of satellite cells after injury. Its receptor, c-met is constitutively expressed on quiescent satellite cells, and it is proposed that the muscle injury release of HGF is involved in activation and/or expansion of muscle precursor cells (39, 40) . LIF and IL-6, also appearing early in the muscle repair process (12-24 h after injury) exerts mitogenic effects on satellite cells (41) . These findings suggest that nerve injury activates multiple factors that, together with IGF-1, are part of a complex sequence of events that regulates the myogenic program. However, the robust myogenic effects of IGF-1 triggered after injury suggests that IGF-1 is a early and dominant factor in regulation of myogenesis.
Several lines of evidence in our study show that IGF-1 augments nerve regeneration. We show that myogenin mRNA expression levels returns to pre-injury levels at a faster rate in IGF-1 transgenic mice. Given that the return of muscle differentiation factor expression to pre-denervation levels is associated with the return of nerve-induced electrical activity (42, 43) , these results show that IGF-1 enhances muscle reinnervation. The accelerated return of γ AchR mRNA levels to pre-denervation levels in IGF-1 transgenic mice exactly parallels the return of myogenin mRNA to pre-denervation levels. These results are supported by studies showing that myogenin regulates the transcription of acetlycholine receptor subunit genes (44) (45) (46) . Further evidence of IGF-1's neurotrophic effects is shown by the increased nerve growth into regenerating muscle, using neurofilament expression as an axonal marker, and the rapid return of saltatory nerve conduction. These results show that the actions of IGF-1 on peripheral nerve regeneration can be attributed to its neurotrophic effects, as wells as to its myogenic effects.
There are several pathways in which IGF-1 accelerates nerve growth. IGF-1 is capable of retrograde transport in the axoplasm of injured sciatic nerve (47) , suggesting that the IGF-1 transgene could directly signal the motor neuron cell body to induce axonal regeneration. The effect of IGF-1 on axonal growth is also supported by studies showing IGF-1-mediated up-regulation of neurofilament and tubulin (48, 49) , which are major structural elements of axons and IGF-1 regulation of myelination (50, 51) . Studies also show that exogenously administered IGF-1 protein accumulates at the neuromuscular junction and neuromuscular nerve bundles and that it increases the size of neuromuscular junction end plates (13, 52) . Furthermore, IGF binding proteins have been localized to muscle synaptic endplates (53) . Enhancement of synaptic formation in IGF-1 transgenic mice would be consistent with the accelerated return of nerve conduction and the return of electrically dependent expression of myogenin, MyoD and AchR's. Therefore, nerve growth induced by the local expression of IGF-1 in muscle could be a result of its multiple targeting to motor neurons, Schwann cells, and the neuromuscular junction.
IGF-1 diminishes muscle atrophy by limiting the decline of muscle mass after nerve injury and accelerating the long-term recovery of muscle mass, compared with injured wild-type muscle. Increased muscle mass may be due, in part, to signaling pathways induced by enhanced innervation of muscle by IGF-1. In addition, the effects of IGF-1 may be also due to its ability to activate satellite cells after nerve injury. Previous reports suggest that muscle mass recovery may require stimulation of satellite cell proliferation and subsequent fusion with myofibers (54, 55) . IGF-1 may act to limit atrophy in this fashion, in part, because inactivation of satellite cells leads to significant reduction of IGF-1-induced muscle hypertrophy (56) . These results, combined with our results that show that IGF-1 transgene enhances myogenesis and nerve growth, indicate that IGF-1 mediates multiple pathways to restore muscle mass after a nerve injury.
In conclusion, these experiments demonstrate that muscle and nerve repair are accelerated by the localized expression of IGF-1 in skeletal muscle. Exerting a myogenic effect, the IGF-1-transgene enhances the activation and differentiation of muscle satellite cells in response to nerve injury. Exerting a neurotrophic effect, the IGF-1 transgene hastens the reestablishment of synaptic connections, as shown by increased innervation and restoration of myogenin and AchR mRNA expression levels and increased nerve conduction rates. The duel role of IGF-1 on motor neuron and muscle regeneration illustrates the benefits of targeting IGF-1 gene expression to skeletal muscle as a potential gene therapeutic application for injured or diseased nerves. expression of muscle differentiation factor mRNA was analyzed after nerve crush injury over two months. Total RNA from gastrocnemius muscle (15 µg) was analyzed for myogenin and AchR subunit gamma by Northern blot. Uniform RNA loading was confirmed by using an 18S rRNA probe. 
